and 12 events per 100 patient-years of exposure for the febuxostat 80-mg, febuxostat 120-mg, and allopurinol groups, respectively. Serious adverse events were reported by 161 patients, with ...

[38] Both febuxostat 40 and 80 mg can be given to patients with mild-to-moderate renal impairment (CL cr of 30–89 mL/min) without dosage adjustments and are as effective as allopurinol in ...